An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.
A surgical team from the Montefiore Einstein Center for Heart and Vascular Care recently received certification training for implanting the SynCardia Total Artificial Heart, a replacement heart implanted in patients at risk of imminent death from heart failure.
Galectin Therapeutics Inc. today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias.
Global Health Partner: SECOND QUARTER 2011. Revenues increased by 14 percent to SEK 180.4 million.
An international team of scientists from the Max-Planck-Institute for Dynamics and Self-Organization, Cornell University the Ecole Normale Supérieure de Lyon, the University Medicine Göttingen, the Rochester Institute of Technology, and the Institut Non-Linéaire de Nice have developed a new low-energy method for terminating life-threatening cardiac fibrillation of the heart.
Cornell scientists, in collaboration with physicists and physician-scientists in Germany, France and Rochester, N.Y., have developed a new - and much less painful and potentially damaging - method to end life-threatening heart fibrillations.
Global Health Partner has acquired OPA, Ortopædisk Privathospital Aarhus A/S in Århus, Denmark, a specialist clinic operating in the fields of orthopaedics and spine surgery.
As our bodies first form, developing cells are a lot like children put on the school bus with their names and addresses pinned to their shirts. The notes identify one as a future heart cell, another as a liver cell, a third as a neuron. And that's what they each grow up to be. But once those cells reach adulthood, changes to those original marching orders caused by aging, disease and other stressors like smoking can precipitate a kind of identity crisis, researchers at the University of Michigan Health System have found.
Responding to a recent study showing that 40% of patients who receive CRT-ICD therapy do not benefit from the device (Sipahi, et al – 6/13/11), Wojciech Zareba, MD, PhD, stated that improving risk stratification of heart failure patients eligible for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) is essential.
Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.
Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with atrial fibrillation (AF) remain "unacceptably high", according to a new report.
BIOTRONIK SE & Co. KG, a worldwide leader in manufacturing cardiac medical devices, announced today that the innovative new Lumax 540 VR-T DX single-chamber implantable cardiac defibrillator (ICD) and Linoxsmart S DX cardiac lead system will be launched this coming week at the EHRA EUROPACE electrophysiology congress in Madrid, Spain.
By 2017, the global electrophysiology mapping and ablation devices market is likely to achieve a value of $2.1 billion, according to a new report on companiesandmarkets.com. An ageing population, an increased number of diagnoses and several clinical studies have encouraged market growth.
Gordon F. Tomaselli, M.D., professor and director of the Division of Cardiology at the Johns Hopkins University School of Medicine, will become president of the American Heart Association (AHA), the nation’s leading voluntary health organization focused on cardiovascular disease and stroke, on July 1.
A protein previously thought not to exist in adult human lungs not only is present in normal and cancerous lung tissue, scientists have found, but it also has a major role in the development of a lethal complication of some lung cancers.
Cypress Pharmaceutical announced today that the Food and Drug Administration (FDA) approved a new drug application (NDA) for ZUTRIPRO Oral Solution (CIII) and REZIRA Oral Solution.
Milestone Pharmaceuticals Inc., a cardiovascular drug development company, announces the completion of a $13 million round of equity financing.
Advanced Cardiac Therapeutics, Inc., a developer of innovative temperature-sensing cardiac ablation systems, today announced that the company has received CE Mark (Conformité Européenne) clearance for its TEMPASURE™ cardiac ablation catheter. The TEMPASURE system is the world's first RF cardiac ablation catheter to offer both saline irrigation and temperature-sensing technology.
Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.